Enzyvant CONNECT® Commercial Co-Pay Program Eligibility Guidelines

Patient must be fully enrolled in Enzyvant CONNECT® Patient Support Program.

Once Enzyvant CONNECT completes the Benefits Investigation, they will determine eligibility for the co-pay program in accordance with the guidelines and criteria.

  • Only commercially insured patients (no federal or state healthcare program, including Medicare, Medicaid, TRICARE, DoD, or any state medical or pharmaceutical assistance program) are eligible
  • Only valid in the United States and US territories (Puerto Rico and US Virgin Islands); this offer is void where prohibited by law, taxed, or restricted
    • California and Massachusetts legislation restricts if a generic equivalent is available
  • The co-pay program is for assistance with the product’s out-of-pocket expenses only
    • No ancillary support (ex: administration, office visits/valuations, blood work, X-rays or other testing, pre-medications/other medication) will be covered
      • Assistance requires that commercial insurance reimburse the product separately (and charge a product coinsurance separately)
    • Insurance cannot cover the entire cost of the prescription
  • Self-pay patients are not eligible
  • Approval is based on calendar year (01/01-12/31)
  • Must have commercial payer approval for the product

Thank you

A care team member will be in touch soon.


You are about to leave RETHYMIC.com.
Click “Confirm” to continue.

You are now leaving the caregiver site. To proceed to the HCP site, click yes to continue. To remain on the caregiver site, click no.

Clinical trial results

RETHYMIC greatly improved survival for children with congenital athymia1

The efficacy and safety of RETHYMIC were evaluated across 10 clinical trials that enrolled a total of 105 children with a follow-up of up to 25.5 years. Of those enrolled, the efficacy of RETHYMIC was evaluated in 95 children.1,2

For children treated with RETHYMIC1:

An estimated


were alive after 1 year

An estimated


were alive after 2 years

Those who were alive 1 year after treatment had a survival rate of


with a median follow-up of 10.7 years

RETHYMIC significantly reduced the number of infections over time1:


fewer children experienced an infection between 6 and 12 months after treatment with RETHYMIC vs the first 6 months after treatment

In a 2-year analysis, fewer children experienced an infection and the average number of infections per child decreased in the second year after treatment compared to the first year after treatment

The safety of RETHYMIC was demonstrated in 105 children across 10 clinical trials1

The most common side effects of RETHYMIC were1,3:

  • Hypertension (high blood pressure)
  • Cytokine release syndrome (overactive immune system)
  • Hypomagnesemia (low magnesium)
  • Rash
  • Renal impairment/failure (decrease of kidney function)
  • Thrombocytopenia (low platelets)
  • Graft versus host disease (a condition in which a person’s T cells attack their own body)

Of the 105 children in the clinical studies, 29 died, including 23 in the first year. The majority of deaths in the first year after receiving RETHYMIC were due to infections.1

These are not all the side effects that can or may occur with RETHYMIC treatment. Please see Important Safety Information below.

After treatment with RETHYMIC, supportive care should continue to be followed at their healthcare provider’s recommendation.1 Explore post-treatment care

Find out how your child’s healthcare provider can begin the referral process.

See what you should expect after your child receives treatment with RETHYMIC.

Enzyvant CONNECT provides support and resources to children with congenital athymia and their caregivers.

Indication and Important Safety Information
Important Safety Information

Infection Control: Immune reconstitution sufficient to protect from infection is unlikely to develop prior to 6-12 months after treatment with RETHYMIC. Immune reconstitution is needed for the body to produce cells in the immune system to fight infection. Your child’s doctor should advise you of infection control measures which should be followed immediately after treatment and until the immune system starts working at a sufficient level. Monitor your child closely for signs of infection, including fever. Your child should be maintained on immunoglobulin replacement and prophylactic antimicrobials until certain criteria are met as determined by your doctor.

Graft versus Host Disease (GVHD): RETHYMIC may cause or make pre-existing GVHD worse. Your child will be monitored for GVHD and treated if needed. Symptoms of GVHD may include fever, rash, enlarged lymph nodes, inflammation of the gastrointestinal system and/or diarrhea.

Autoimmune Disorders: Autoimmune-related adverse events occurred in patients treated with RETHYMIC. These events included: low platelets, low white blood cells, protein in urine, low red blood cells, hair loss, poor thyroid function, inflammation of liver, inflammation of the joints, inflammation of the spinal cord, loss of pigment in the skin, eyes and hair, overactive thyroid function, and loss of function of the ovaries. Your doctor will monitor your child regularly including performing blood tests.

Kidney Disease: Treatment with RETHYMIC is a risk factor for death in patients with pre-existing kidney disease.

Cytomegalovirus (CMV) Infection: In clinical studies with RETHYMIC, 4 out of 4 patients with pre-existing CMV infection prior to the implantation with RETHYMIC died. Talk to your doctor about the benefits/risks of treatment if your child has pre-existing CMV infection.

Cancer: Due to your child’s weakened immune system, there is increased risk of developing certain cancers. Your child’s doctor will monitor your child through testing for Epstein-Barr virus (EBV) and cytomegalovirus (CMV), which are two viruses that can cause cancer.

Transmission of Serious Infections: Because RETHYMIC is made from human tissue, and animal products are used in the manufacturing process, transmission of infectious diseases may occur.

Vaccinations: Your child should not receive any vaccinations until he or she has met certain requirements set by your doctor. Talk to your child’s doctor prior to any vaccinations.

Anti-HLA Antibodies: Prior to receiving RETHYMIC your child will be tested for HLA antibodies, which are proteins that may be present in your child’s blood. If your child has these antibodies, he/she will need to receive RETHYMIC from a donor that does not express those HLA proteins.

HLA Typing: If your child has received a hematopoietic cell transplantation (HCT) or a solid organ transplant, they will have a test to look for specific antibodies that could interfere with the effect of RETHYMIC. If they are present, then it will be necessary to receive RETHYMIC from a certain group of donors that do not have these proteins.

Deaths: 105 children participated in the clinical studies of RETHYMIC. 29 of the patients died, including 23 in the first year after implantation of RETHYMIC.

What are the most common side effects with RETHYMIC?

The most common side effects with RETHYMIC are hypertension (high blood pressure), cytokine release syndrome, rash, hypomagnesemia (low magnesium), renal impairment / failure (decrease of kidney function), thrombocytopenia (low platelets), and graft versus host disease.

These are not all of the possible side effects of RETHYMIC. Talk to your child’s doctor about any side effect that bothers your child or does not go away.

You are encouraged to report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/safety/medwatch.


RETHYMIC® (allogeneic processed thymus tissue–agdc) is indicated for immune reconstitution in pediatric patients with congenital athymia.

RETHYMIC is not for use in patients who have been diagnosed with severe combined immunodeficiency (SCID).

References: 1. RETHYMIC [package insert]. Marlborough, MA: Sumitomo Pharma America, Inc; 2023 2. Markert ML, Gupton SE, McCarthy EA. Experience with cultured thymus tissue in 105 children. J Allergy Clin Immunol. 2022;149(2):747-757. doi:10.1016/j.jaci.2021.06.028 3. Collins C, Sharpe E, Silber A, Kulke S, Hsieh EWY. Congenital athymia: genetic etiologies, clinical manifestations, diagnosis, and treatment. J Clin Immunol. 2021;41(5):881-895. doi:10.1007/s10875-021-01059-7